Horizon's Revised TED Indication Should Help Tepezza
Good News For Amgen, But Viridian Looms As Competition
With Tepezza now clearly labeled for all thyroid eye disease patients, rather than just acute cases, Amgen can be more optimistic about economics around of its Horizon acquisition, analysts suggest.
